Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Victoza will 'not be overnight success' in China

This article was originally published in Scrip

Executive Summary

Novo Nordisk does not expect its type 2 diabetes treatment Victoza (liraglutide) to become "a huge product overnight" in China, following approval of the drug by the State Food and Drug Administration (SFDA). However, it intends to use its "extensive experience and leadership market position" in China, where it has "70% of the insulin market", to boost uptake of the once-daily human glucagon-like peptide-1 (GLP-1) analogue, which is approved as an add-on to metformin or sulfonylurea, chief science officer Mads Krogsgaard Thomsen told Scrip.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts